Low-density lipoprotein receptor–negative compound heterozygous familial hypercholesterolemia: Two lifetime journeys of lipid-lowering therapy

2017 ◽  
Vol 11 (1) ◽  
pp. 301-305 ◽  
Author(s):  
Reyhana Yahya ◽  
Monique T. Mulder ◽  
Eric J.G. Sijbrands ◽  
Monique Williams ◽  
Jeanine E. Roeters van Lennep
Keyword(s):  
Familial Hypercholesterolemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Compound Heterozygous ◽  
Lipid Lowering Therapy ◽  
Low Density ◽  
Lipoprotein Receptor ◽  
Lowering Therapy ◽  
Density Lipoprotein Receptor

scholarly journals Homozygous familial hypercholesterolemia: modern aspects of pathogenesis, diagnostics and treatment

2018 ◽  
pp. 253-259
Author(s):  
V. К. Zafiraki ◽  
Е. D. Kosmacheva ◽  
I. N. Zakharova ◽  
V. A. Korneva ◽  
A. V. Susekov
Keyword(s):  
Familial Hypercholesterolemia ◽  
Genetic Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Premature Death ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Low Density ◽  
Homozygous Familial Hypercholesterolemia ◽  
Lowering Therapy

Homozygous familial hypercholesterolemia is a rare genetic disease featuring extremely high of low-density lipoprotein blood level, cutaneous and tendon xanthomas and accelerated atherosclerosis with often manifestions in the first 2 decades of life, resulting to premature death due to atherosclerosis-related diseases. Modern combined lipid-lowering therapy is able to increase life duration considerably for these patients.

Sign in / Sign up

Export Citation Format

Share Document